JP2002087981A - Improving agent for metabolic disorder against sugar and lipid - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a health food or a medicine capable of improving lipid metabolism disorder and further sugar metabolism disorder. SOLUTION: An improving agent for metabolic disorder against sugars and lipids containing a mycelium extract obtained from a cultured product of mycelium of Basidiomycota. The Basidiomycota is preferably Lenthinula edodes (Berk.) Sing., Hydnum and Flammulina Velutipes (Fr.) Sing. The mycelium extract of Basidiomycota is preferably obtained as follows: Basidiomycota is inoculated on a solid medium comprising bagasse as the base material; the solid medium containing the mycelium obtained by growing the inoculated mycelium is disintegrated; water and one or more kinds of enzymes selected from cellulases and proteases are added to the disintegrated solid medium kept at 30-50 deg.C; the solid medium is crushed and ground in the presence of the enzyme to obtain a mycelium extract of Basidiomycota; and the extract is heated up to 95 deg.C to deactivate the enzyme and sterilize the product.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

The present invention relates to an agent for improving carbohydrate lipid metabolism abnormality, and more particularly to an agent for improving carbohydrate lipid metabolism abnormality containing a basidiomycete mycelium extract such as a Shiitake mushroom mycelium extract.

[0002]

2. Description of the Related Art Basidiomycetes, such as shiitake mushrooms, matsutake mushrooms, and enoki mushrooms, have been edible since ancient times, and some mushrooms, such as mushrooms belonging to the basidiomycete Sarnoshikomiaceae, have been widely used as herbal medicines. On the other hand, various methods for extracting an active ingredient from such basidiomycetes have been proposed. For example,
(1) Japanese Patent Application Laid-Open No. 54-46859 discloses that basidiomycetes are inoculated into a medium mainly composed of bagasse, the mycelium is propagated, and the mycelial propagation medium is pressed to collect the active ingredient. A method for producing a health food is disclosed.

[0003] The applicant of the present application is (2) Japanese Patent Application No. 62-341.
In No. 23, "A solid medium containing mycelia obtained by inoculating enoki mushroom fungi on a solid medium based on bagasse and then growing mycelia was 30% by weight through a 12 mesh mesh.
Unbundled as follows, and in this unbundled solid medium,
Water and one or more enzymes selected from cellulases, proteases or glucosidases are added, and the solid medium is crushed and crushed in the presence of the enzymes so that at least 70% by weight or more of the bagasse fiber passes through 12 mesh. A method for extracting useful components from enoki mushroom mycelium and bagasse medium, wherein the enzyme is inactivated and sterilized by heating to a temperature of up to 95 ° C. "Has been proposed.

In (3) Japanese Patent Publication No. 60-23826, the applicants of the present invention have reported that a health care method is the same as that described in Japanese Patent Application No. 62-34123, except that Shiitake fungi is used as the inoculum. A method for producing a beverage is proposed.
In this publication, the resulting health drinks have a hypotensive effect,
It is described as having a diuretic effect and a fatigue recovery effect.

(4) Japanese Patent Application Laid-Open No. 57-170173 discloses that a culture medium is prepared by using a raw material containing a large amount of raw sugar and plant fiber such as sugar cane or radish, and to inoculate edible mushrooms such as shiitake mushrooms. After inoculation and culturing the mycelium, the culture medium immediately before or immediately after the occurrence of the fruiting body is crushed, hydrated, and heated to cause autolysis of the mycelium and the active ingredient contained in the mycelium. A method is disclosed for producing a powdered food containing the active ingredient of edible mycelium and dietary fiber, which is leached into a culture medium, then dried and finely pulverized. The publication states that the powdered food obtained by this method is effective for colon cancer, arteriosclerosis, diabetes and the like.

[0006] The applicant of the present invention has disclosed in (5) Patent No. 25
No. 19785 (JP-A-2-107171),
A method for producing a dietary fiber-containing food by inoculating an enokitake mushroom mycelium into a solid medium containing plant fiber consisting of corn, bran and rice bran and water, inoculating enokitake mycelium, crushing the medium after culture, and drying the medium. The publication proposes that when a food obtained by this method is consumed, prevention of constipation, prevention of obesity, diabetes, arteriosclerosis, promotion of elimination of toxic substances in food, improvement of self-protection ability, etc. can be expected. Is described.

[0007] (6) JP-A-2-134325 discloses an AIDS therapeutic agent comprising a component extracted from a mycelium culture of Shiitake fungi, a kind of basidiomycete. In addition, (7) “Mushroom Chemistry and Biochemistry” (Mizuno and Kawai, edited by Gakkai Shuppan Center) states that mushroom dietary fiber can be expected to have pharmacological effects and prevent colon and rectal cancers.
It is described that the enokitake mushroom extract has a carcinogenic preventive effect that has been proven in animal experiments.

(8) "Mushroom Antitumor Research 20 Years" (Ikegawa et al., Published by Nagano Prefectural Rural Industries Research Institute, March 1989
(Proc. 1) published on January 1) states that profuramine isolated from the mycelium of Enokitake mushroom functions as an anticancer agent, has no toxicity when administered orally, and shows no other side effects. Further, the present inventors have proposed (9) JP-B-60-238.
No. 26, found that the Shiitake mushroom mycelium extract obtained by the same method as described in JP-A No. 26 has an HIV-type virus activity inhibitory effect, and this method was disclosed in JP-A-7-173070 (Japanese Patent No. 3017630). HIV obtained
A virus activity inhibitor has been proposed.

[0009] As described above, the mycelium extract of Shiitake mushroom, the mycelium of Enokitake mushroom or its extract, and the like have been conventionally used in cancer prevention, constipation prevention, obesity, diabetes, arteriosclerosis prevention, and elimination of toxic substances in foods. It has been reported that there are various effects that are effective for maintaining and promoting health, such as improving self-protection ability. However, in addition to the above-mentioned effects, what other effects do basidiomycete mycelium extracts, such as shiitake mushroom mycelium extracts, extracted from basidiomycete shiitake mushrooms (mycelium cultures) have? The point is often unknown.

Therefore, the present inventor conducted intensive studies on the pharmacological action of basidiomycete mycelium extract, which has been conventionally used and used in Kampo medicines, such as Shiitake mushroom mycelium extract. Surprisingly, it has been found that the basidiomycete mycelium extract has a remarkable effect of improving carbohydrate / lipid metabolism abnormality, and the present invention has been completed.

[0011]

SUMMARY OF THE INVENTION The object of the present invention is to solve the problems associated with the prior art as described above, and can improve abnormalities in lipid metabolism, can also improve abnormalities in carbohydrate metabolism, etc. An object of the present invention is to provide an agent for improving abnormalities in carbohydrate lipid metabolism, which is excellent in safety without fear.

[0012]

SUMMARY OF THE INVENTION The agent for improving carbohydrate lipid metabolism abnormality according to the present invention is characterized by containing a basidiomycete mycelium extract extracted from a basidiomycete mycelium culture. Examples of the basidiomycetes include Shiitake fungi, Yamabushi mushrooms, Enokitake mushrooms, and eryngii. In the present invention, the mycelium extract of the basidiomycetes is a mycelium obtained by inoculating basidiomycetes such as Shiitake fungi on a solid medium based on bagasse and then growing the mycelia. Is unbundled, and one or more of water and an enzyme selected from cellulase or protease are added to the unbundled solid medium while maintaining the solid medium at 30 to 50 ° C., and The solid medium is ground and crushed in the presence of an enzyme to extract a basidiomycete mycelium extract such as a Shiitake mushroom mycelium extract, and then heated to a temperature of up to 95 ° C. to inactivate and sterilize the enzyme. Desirably.

When such an agent for improving abnormalities in carbohydrate lipid metabolism, for example, is orally ingested, abnormalities in lipid metabolism can be remarkably improved, and abnormalities in carbohydrate metabolism in diabetic patients can be improved. Excellent in safety.

[0014]

DETAILED DESCRIPTION OF THE INVENTION Hereinafter, the agent for improving abnormalities of carbohydrate lipid metabolism according to the present invention will be described in detail. [Manufacture of an agent for improving abnormalities in carbohydrate lipid metabolism] The agent for improving abnormalities in carbohydrate lipid metabolism according to the present invention contains a mycelium extract of basidiomycetes.

[0015] Basidiomycota has been edible as an edible fungus in Japan since ancient times or used in Chinese medicine.
les) mushrooms include Tricholoma Matsutake Ito e
t Imai.), Shiitake mushrooms (Lentinula edodes (Berk.) Sing.), Enoki mushrooms (Flammulina Velutipes (Fr.) Sing.), Plain mushrooms (Ple
urotus ostreatus (Jacq.Ex Fr) Kummer), Nameko (Pho
liota nameko (I.Ito) S.Ito et IMAI), Boletus (Bolet
us Dill.ex Fr.) and Lyophyllum shimeji (Kawa
m.) Hongo), mushroom (Lactarius volemus (Fr.) Fr.),
Eryngii (pleurotus eryngii) and the like.

[0016] The mushrooms of the order Aphyllophorales include those of the order Aphllophorales.
t.), Kawara mushroom (Coriolus versicolor (Fr.) Quel.), Mannen mushroom or Ganoderma lucidum (W. Curt. ex F
r.) Karst.), Maitake (Grifola frondosa (Fr.) SFGray),
Mesimakov (P. yucatensis (Murr.) Imaz.,) And the like.

The mushrooms of the order Auriculariales or Tremellales include the jellyfish Auri
cularia auricula (Hook.) Underw.), white jellyfish (Trem
ellinea fuciformis Berk.). As the mushrooms of the chanterelle (cantharellales), the mushroom family (Hy
dnaceae), ie, mushrooms (hydnum).

In the present invention, among these basidiomycetes,
Shiitake mushrooms (Lentinula edodes (Berk.) Sing.), Yamabushi mushrooms, and enoki mushrooms (Flammulina Velutipes (Fr.) Sing.) Are preferably used. In the present invention, these basidiomycetes can be used alone or in combination of two or more. Many of these basidiomycetes are described in "Encyclopedia of Mushrooms" (edited by Katsuya Nakamura, Asakura Shoten, 1989), "Methods for Mushroom Culture"
(Inoide Yanosuke, Earth Company, 5th revised edition, 1985) or "Primary Color Japanese Fungi Encyclopedia" (Co-authored by Imazeki et al., Kikusha, Showa 5)
8 years, 27 prints).

There is no particular limitation on the method for producing a basidiomycete mycelium extract such as a Shiitake mushroom mycelium extract. For example, in the case of a Shiitake mushroom mycelium extract, as described in JP-A-2-134325, After the substance is self-digested as necessary, it may be obtained by extracting with hot water and precipitating the hot water extract in alcohol.If necessary, the precipitate may be further fractionated by a chromatography column. The eluted fraction may be fractionated and used with ethylene glycol or the like.

In the present invention, the mycelial extract of Shiitake mushrooms is particularly preferable in view of the effect of improving the abnormalities of carbohydrate metabolism and lipid metabolism, and is prepared using the method described in Japanese Patent Publication No. 23826/1985. Is desirable. Also, in the case of other basidiomycete mycelium extracts as described above other than the Shiitake mushroom mycelium extract, those prepared by the same method as the Shiitake mushroom mycelium extract are preferable.

Hereinafter, an example of the method for preparing the Shiitake mushroom mycelium extract will be described in detail. To prepare the Shiitake mushroom mycelium extract, first, water, preferably pure water, is appropriately mixed in a solid medium consisting of bagasse, and then the Shiitake mushroom is inoculated. In addition, besides rice bran, if necessary, phosphorus,
Minerals such as iron and germanium, peanut epidermis, brown rice and the like may be added.

Next, the medium inoculated with the Shiitake mushrooms is placed in a culture room in which the temperature and humidity are controlled and the illuminance is also controlled, and the mycelium is grown. Mycelia spread on solid media, and immediately before and after the onset of fruiting bodies,
Unpack the bagasse-based fibrous material, and pass 12 mesh
It is desirable that the content be 0% by weight or less. In addition,
It is preferable that the bagasse-based medium be unbound at a time immediately before and immediately after the occurrence of the fruiting body as described above, but may be performed at a time after the fruiting body has grown considerably.

The solid medium thus unbundled is mixed with water and one or more enzymes selected from the group consisting of cellulase, protease and glucosidase.
Add while maintaining at ５０50 ° C. As the enzyme to be added, cellulase is preferable. The amount of the enzyme to be added is preferably 0.5 to 5 g, preferably 1 to 3 g, per kg of the solid medium. The water is preferably pure water containing no ions such as metal ions, and 1 kg of pure water, preferably 2 to 6 kg, is added to 1 kg of the unbundled medium to form a bagasse-containing mixture.

Next, the Shiitake mushroom mycelium extract is extracted from the bagasse-containing mixture. To extract the Shiitake mushroom mycelium extract in this manner, the medium-containing mixture is circulated using, for example, a gear pump equipped with a transmission. It is desirable to add a pulverizing and grinding action to the medium so that about 70% by weight or more of the bagasse fiber passes through 12 mesh.

The pulverization and crushing of the bagasse-containing mixture may be carried out while maintaining the temperature of the mixture at 30 to 50 ° C., or may be carried out while gradually increasing the temperature from the above temperature. It is preferable to perform while. When the water temperature becomes 60 ° C or higher, preferably 70 ° C or higher,
When air at room temperature is injected into the bagasse-containing mixture, the air bubbles are rapidly heated and destroyed, impacting the bagasse fibers and extracting the active ingredient more efficiently.

Next, the bagasse-containing mixture thus treated is further heated to a temperature of up to 95 ° C., preferably about 75 to 90 ° C., and maintained at this temperature for several tens of minutes. Inactivate the enzymes in the mixture,
When the mixture is sterilized, a Shiitake mushroom mycelium extract is obtained.
In addition, the obtained Shiitake mushroom mycelium extract may be used as needed.
It may be filtered using a filter cloth of about 120 to 120 mesh, preferably about 60 to 100 mesh.

The shiitake mushroom mycelium extract thus obtained can be used after being concentrated, or can be freeze-dried and used as a powder. Although the preferred method of preparing the Shiitake mushroom mycelium extract has been described in detail, the other basidiomycete mycelium extract used in the present invention may also be replaced with the above Shiitake mushroom, by using Reishi, Enoki mushroom, Mesimakobu, Yamabushi mushroom It can be prepared in the same manner as described above except that basidiomycetes such as maitake, maitake and eryngii are used.

[0028] The basidiomycete mycelium extract such as the above-mentioned Shiitake mushroom mycelium extract may be contained in the carbohydrate lipid metabolism abnormality improving agent of the present invention in any amount. Such an agent for improving abnormalities of carbohydrate lipid metabolism may be orally administered in various dosage forms such as granules, liquids, tablets and capsules, and may also be developed as an injection for use in persons with abnormal carbohydrate lipid metabolism. It is possible. In addition, the agent for improving abnormalities in carbohydrate lipid metabolism containing the undiluted solution of mycelium extract described above has an effect of improving abnormalities in carbohydrate metabolism as well as an effect of improving abnormalities in lipid metabolism. Although it can be administered to an abnormal person, for example, it can be administered after appropriately diluting it with purified water, alcohol or the like.

As described above, when the agent for improving abnormalities of carbohydrate lipid metabolism according to the present invention is administered to a person having abnormal lipid metabolism and a person having abnormal carbohydrate metabolism, the symptoms thereof can be improved and the patient can survive for a long period of time. Can be. As described above, the agent for improving abnormalities in carbohydrate lipid metabolism according to the present invention can improve abnormalities in carbohydrate metabolism while improving abnormalities in carbohydrate metabolism, and can also prolong the survival period thereof, as follows. It seems to be due to various reasons.

That is, according to the study of the present inventors, the agent for improving abnormalities in carbohydrate lipid metabolism comprising a basidiomycete mycelium extract such as the Shiitake mushroom mycelium extract is derived from a basidiomycete mycelium such as the Shiitake mushroom mycelium. Many active ingredients are extracted from the solid medium in which the basidiomycete mycelium such as Shiitake mushroom mycelium is cultured, and these components (unidentified) act comprehensively. It is thought that not only abnormalities in lipid metabolism but also abnormalities in carbohydrate metabolism are improved.

[0031]

Industrial Applicability According to the present invention, abnormalities in lipid metabolism can be improved, abnormalities in carbohydrate metabolism can be improved, the life can be prolonged, and health foods excellent in safety without side effects can be obtained. Alternatively, there is provided an agent for improving abnormalities in carbohydrate lipid metabolism, which is a medicament. To further add here, according to a survey by the Ministry of Health and Welfare, the number of diabetic patients in Japan is estimated at 6
It is 900,000, indicating that one in ten adults has diabetes. In addition, the Diabetes Reserve Army at the border between diabetes and health (borderline diabetes)
Including 13.7 million patients, the number will reach 13.7 million.

The Ministry of Health and Welfare research team predicts that the number of patients will increase to 11.74 million by 2010. However, only about 2.2 million patients are currently being treated at medical institutions. Diabetes mellitus develops due to aging and daily living habits. However, since there are few subjective symptoms, serious complications such as nephropathy, cataract and neuropathy may occur unless treated early. In addition, with the onset of diabetes, excess carbohydrates are converted into lipids in the living body, and also induce abnormal lipid metabolism.

As described above, excess carbohydrates and lipids flowing in the blood are deposited on the blood vessel wall, inflammation is caused by infiltration of inflammatory lymphocytes and platelets, and arteriosclerosis, which is a cause of ischemic disease, is caused. Will do. Cardiac disease and stroke, which are ischemic diseases, are among the three leading causes of death in Japanese people. It is important to treat and prevent abnormal carbohydrate and lipid metabolism to treat and prevent these diseases. It is considered.

Japanese diabetic patients have type 2 diabetes (NI
Since the DDM type accounts for 80% or more, a drug for overcoming insulin resistance has been developed as a drug for treating diabetes, but an effective drug for treating diabetes with few side effects has not yet been developed. Diabetes requires a long-term diet or exercise therapy to control blood sugar levels, but if blood sugar levels cannot be controlled well, pharmacotherapy will be performed (implemented). However, to date, there is no therapeutic agent that can be used safely for a long period of time, and development of a new therapeutic agent for diabetes has been desired.

The basidiomycete mycelium extract such as the Shiitake mushroom mycelium extract used in the present invention is highly safe, can be taken for a long period of time, and improves blood glucose level by improving abnormal carbohydrate metabolism and lipid metabolism. It is thought that the blood lipid level can be controlled normally, and the significance of the development of the agent for improving abnormal carbohydrate lipid according to the present invention is significant.

[0036]

EXAMPLES Hereinafter, the present invention will be described more specifically based on examples, but the present invention is not limited to these examples.

[0037]

[Preparation Example 1] [Preparation of an agent for improving abnormalities in carbohydrate lipid metabolism comprising a mycelium extract of Shiitake mushroom] After inoculating a solid medium consisting of 90 parts by weight of bagasse and 10 parts by weight of rice bran with moderately pure water, then inoculating Shiitake mushroom inoculum. Then, the cells were placed in a culture room where the temperature and humidity were controlled, and the mycelium was grown. After the mycelium spread on the solid medium, the fibrous material of the bagasse base material was unbundled so that the amount passed through the 12 mesh became 24% by weight or less. To 1.0 kg of the unbound medium, 3.5 liters of pure water and 2.0 g of purified cellulase were added while maintaining the solid medium at 40 ° C. to obtain a bagasse-containing mixture.

Then, while circulating the culture medium-containing mixture with a gear pump equipped with a transmission, a crushing and crushing action is applied to the solid culture medium in the gear portion of the pump for about 200 minutes, so that about 80% by weight of the bagasse fiber passes through 12 mesh. I made it. The pulverization and grinding of the bagasse-containing mixture were performed while gradually increasing the temperature of the mixture. Thereafter, the bagasse-containing mixture was further heated to 90 ° C. and left for 30 minutes.

The enzyme was inactivated by heating to 90 ° C. and sterilized. The resulting culture medium-containing mixture was filtered using a 60 mesh filter cloth to obtain a Shiitake mushroom mycelium extract containing microsuspension. This Shiitake mushroom mycelium extract was powdered by freeze drying.

[0040]

Preparation Examples 2 to 3 In the same manner as in Preparation Example 1, except that Enoki mushroom inoculum (Preparation example 2) and Yamabushi mushroom inoculum (Preparation example 3) were used instead of Shiitake mushroom inoculation. An enoki mushroom mycelium extract powder and a Yamabushi mushroom mycelium extract powder were obtained.

[0041]

[Test Example 1] Using the mushroom mycelial extract (powder) obtained in Preparation Example 1 above, a saccharide lipid metabolism abnormality improving agent was used.
The effect of ameliorating these diseases on mice with abnormal lipid metabolism and abnormal carbohydrate metabolism was examined. <Test method> A group of male ddY mice weighing 20 to 30 g: 29 mice were prepared, 24 of them were fasted for 20 hours, and then “streptodotocin (STZ)”
Was injected intravenously in an amount of 100 mg / kg. This “streptodotocin (STZ)” is known as a drug that causes diabetes by destroying β-cells of the pancreas.

Then, immediately, 100 g of the normally cultivated feed powder
A group fed with 3.0 g of Shiitake mushroom mycelium extract (powder) was fed as a feed (A): 12 animals, and a group fed normal feed only (B): 12 animals, and raised for 4 weeks. . The remaining five mice (group (C)) were fed with normal feed powder to normal mice not receiving the above-mentioned intravenous injection of STZ, and reared for 4 weeks.

In the fourth week, rats of each group of (A) to (C) were bled while being bred without fasting.
Neutral lipid content (triglyceride content), total cholesterol content, and glucose content in serum were measured. Table 1 shows the results.

[0044]

[Table 1]

As is clear from the comparison between the test groups (A) and (B) in Table 1, when the Shiitake mushroom mycelium extract (powder) was administered, mice with abnormal carbohydrate metabolism (mice in which pancreatic β-cells were destroyed) A statistically significant improvement in serum total cholesterol level and serum triglyceride level (neutral lipid level) was observed. In addition, as is clear from the test groups (A) and (C) in Table 1, when the mice were administered Shiitake mushroom mycelium extract (powder) irrespective of the presence or absence of abnormal carbohydrate metabolism, the tendency of improvement of abnormal lipid metabolism was observed. Can be

The same effect as described above can be obtained when a Yamabushi mushroom mycelium extract or an Enokitake mushroom mycelium extract is used instead of the Shiitake mushroom mycelium extract.

[0047]

[Test Example 2] Using an agent for improving abnormalities of carbohydrate lipid metabolism, comprising the mushroom mycelium extract (powder) obtained in Preparation Example 1 above,
"Effects on the rise of cholesterol level in rabbits caused by high cholesterol load" were examined. <Test method> ・ Administration of Shiitake mushroom mycelium extract to cholesterol-loaded rabbits After breeding 32 male Japanese white rabbits for 2 weeks as a preliminary breed, cholesterol was first adjusted to a concentration of 1% in a normal diet as a basic diet. (Hereinafter referred to as “cholesterol diet”) was orally ingested and bred for 8 weeks.

Thereafter, the control group (8 birds) was further fed a cholesterol diet and raised. On the other hand, the remaining 24 rabbits were tested for their effects by adding a Shiitake mushroom mycelium extract as an experimental group described below. 1% Shiitake mycelium extract-added diet group: A diet in which the Shiitake mushroom mycelium extract is added to the above cholesterol diet at 1% is administered.

2% Shiitake mycelium extract-added diet group: A diet obtained by adding the Shiitake mushroom mycelium extract to the above-mentioned cholesterol diet at 2% is administered. 4% Shiitake mushroom mycelium extract-added diet group: A diet obtained by adding a Shiitake mushroom mycelium extract to the above-mentioned cholesterol diet at 4% is administered. The control group and each experimental group each consisted of eight birds and were reared under the same environment, respectively, for further eight weeks.

After all, the rabbits in the control group and each experimental group had consumed a diet containing 1% cholesterol for 16 weeks from the start of the experiment. At the start of the experiment and for 12 weeks, 16
Total cholesterol in blood (TC) at week
Was measured. During the breeding period, there was no significant difference in changes in the weight of rabbits in each group.

Table 2 shows the change in the total blood cholesterol concentration of each group. Note that "before the experiment" indicates a value immediately before administration of a cholesterol diet.

[0052]

[Table 2]

The blood total cholesterol concentration in the experimental group tended to decrease by about 10% in 12 weeks and 16 weeks as compared with the control group. In particular, in the diet group supplemented with 1% Shiitake mushroom mycelium extract, the cholesterol level remained lower than that in the control group during the breeding period, which is considered to be the result of the lipid metabolism improving effect of the Shiitake mushroom mycelium extract.

[0054]

[Test Example 3] Using the Shiitake mushroom mycelium extract (powder) obtained in Preparation Example 1 above, a carbohydrate lipid metabolism abnormality improving agent was used.
"Effects on glucose elevation in mice due to glucose load" were examined. <Test method> Male ddY mice weighing 28 to 33 g were prepared in three groups (I), (II) and (III) (8 mice in each group). % Sugar water (1
g / 10 ml / Kg), and blood was collected 30 minutes after the administration of the sugar water to determine the glucose level in the serum (control group).

In the group (I), the shiitake mushroom mycelium extract (powder) was added 1000 m 30 minutes before administration of the sugar water.
g / kg was orally administered (Shitake mushroom mycelium extract administration group). In addition, neither sugar water nor shiitake mushroom mycelium extract was given to the group (III) (untreated group). Table 3 shows the results.

[0056]

[Table 3]

According to Table 3, when the mycelium extract of Shiitake mushroom was administered before the administration of the sugar water, it was found that the increase in the serum glucose level of the mouse was inhibited by 6.4%. This indicates that ingestion of the Shiitake mushroom mycelium extract in the short term also has an effect of improving postprandial hyperglycemia. Ingestion of the mycelial extract of Shiitake mushrooms in this way contributes to the suppression of excessive secretion of insulin, because of the effect of suppressing blood glucose elevation, and consequently concerns about the onset of diabetes due to chronic chronic satiety and lack of exercise. On the other hand, it is expected to contribute to the prevention and treatment of diabetes and the prevention and treatment of its complications.

It should be noted that the spontaneously hypertensive model “SH”
In "R rats", a decrease in sugar processing capacity is observed, but the same is said in the case of human hypertensive patients,
It is expected that the administration of Shiitake mushroom mycelium extract to such hypertensive patients will suppress an increase in blood sugar level and improve hypertension. The same effect as described above can be obtained when a Yamabushi mushroom mycelium extract, an Enokitake mushroom mycelium extract, or the like is used instead of the Shiitake mushroom mycelium extract.

Claims (4)

[Claims] 1. An agent for improving abnormalities in carbohydrate lipid metabolism, comprising a basidiomycete mycelium extract extracted from a basidiomycete mycelium culture. 2. The agent according to claim 1, wherein the basidiomycete is at least one of Shiitake fungi, Yamabushi mushroom fungus and Enoki mushroom fungus. 3. The basidiomycete mycelium extract is inoculated with basidiomycetes on a bagasse-based solid medium, and then the mycelium is obtained. Adding one or more of water and an enzyme selected from cellulase or protease to the unbound solid medium while maintaining the solid medium at 30 to 50 ° C;
The solid medium is ground and crushed in the presence of an enzyme to extract a basidiomycete mycelium extract, and then heated to a temperature of up to 95 ° C. to inactivate the enzyme and sterilize the basidiomycete mycelium extract. The saccharide lipid metabolism abnormality improving agent according to claim 1, wherein 4. The agent according to claim 3, wherein the basidiomycete is any one or more of Shiitake fungi, Yamabushi mushroom fungus and Enoki mushroom fungus.